Many studies showed that DPP4 inhibition attenuated endothelial dysfunction, inflammation, and atherosclerotic process, but available phase IV studies did not associate the use of gliptins with reduced CV events in T2DM. Here, DPP4 is linked to type 2 diabetes mellitus.